In the present study, we explored the role of TP53 mutations on the prognosis of patients with stage I NSCLC by analyzing three public datasets from TCGA, in particular those patients with surgically resected stage IA disease. This evidence concerns the gene TP53 and non-small cell lung carcinoma.